恒瑞医药(600276.SH)：HRS-2329片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-2329 tablets, an innovative anti-tumor drug developed by the company [1] Group 1 - HRS-2329 tablets are designed for the treatment of advanced solid tumors with RAS mutations or amplifications [1] - The drug has shown promising anti-tumor activity in preclinical animal models [1] - The clinical trials are set to commence shortly following the approval [1]